EEG microstate complexity for aiding early diagnosis of Alzheimer’s disease by Tait, Luke et al.
                          Tait, L., Tamagninie, F., Stothart, G., Barvas, E., Monaldini, C.,
Frusciante, R., Volpini, M., Guttmann, S., Coulthard, E., Brown, J. T.,
Kazanina, N., & Goodfellow, M. (2020). EEG microstate complexity for
aiding early diagnosis of Alzheimer’s disease. Scientific Reports, 10,
[17627 (2020)]. https://doi.org/10.1038/s41598-020-74790-7
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1038/s41598-020-74790-7
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Nature Research at
https://www.nature.com/articles/s41598-020-74790-7 . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the




Scientific Reports |        (2020) 10:17627  | https://doi.org/10.1038/s41598-020-74790-7
www.nature.com/scientificreports
EEG microstate complexity 
for aiding early diagnosis 
of Alzheimer’s disease
Luke Tait1,2,3,4*, Francesco Tamagnini5,6, George Stothart7, Edoardo Barvas8, 
Chiara Monaldini8, Roberto Frusciante8, Mirco Volpini8, Susanna Guttmann8, 
Elizabeth Coulthard9, Jon T. Brown6, Nina Kazanina10 & Marc Goodfellow1,2,3,11
The dynamics of the resting brain exhibit transitions between a small number of discrete networks, 
each remaining stable for tens to hundreds of milliseconds. These functional microstates are thought 
to be the building blocks of spontaneous consciousness. The electroencephalogram (EEG) is a useful 
tool for imaging microstates, and EEG microstate analysis can potentially give insight into altered 
brain dynamics underpinning cognitive impairment in disorders such as Alzheimer’s disease (AD). 
Since EEG is non-invasive and relatively inexpensive, EEG microstates have the potential to be useful 
clinical tools for aiding early diagnosis of AD. In this study, EEG was collected from two independent 
cohorts of probable AD and cognitively healthy control participants, and a cohort of mild cognitive 
impairment (MCI) patients with four-year clinical follow-up. The microstate associated with the 
frontoparietal working-memory/attention network was altered in AD due to parietal inactivation. 
Using a novel measure of complexity, we found microstate transitioning was slower and less complex 
in AD. When combined with a spectral EEG measure, microstate complexity could classify AD with 
sensitivity and specificity > 80%, which was tested on an independent cohort, and could predict 
progression from MCI to AD in a small preliminary test cohort of 11 participants. EEG microstates 
therefore have potential to be a non-invasive functional biomarker of AD.
Alzheimer’s disease (AD) is a neurological disorder in which progressive neurodegeneration and synaptic dys-
function result in impairments in a range of cognitive domains. Early diagnosis of AD has a wide range of clinical, 
social, and economic  benefits1–3, but at present the definitive diagnosis of AD is made only post-mortem. Avail-
able tools for a diagnosis of probable AD in the clinic are mostly based on cognitive, biochemical, and neuroim-
aging  markers4. Biochemical and neuroimaging techniques such as CSF or PET measurements of amyloid and 
tau have high sensitivity, but large multi-centre studies of CSF markers have shown specificity as low as 72% for 
prodromal diagnosis of  AD5. The specificity of PET scans is higher, around 83–87%6.
Molecular and neuroimaging markers do not measure brain function, so combining them with functional 
markers is likely to further increase sensitivity and specificity of early diagnosis of AD. Neuropsychological 
evaluation assesses brain function, is non-invasive and relatively inexpensive, but is time consuming, subject to 
cultural and personal bias, and is unsuitable for prodromal diagnosis of AD in cognitively homogeneous cohorts 
of mild cognitive impairment (MCI) patients.
Electroencephalography (EEG) is a non-invasive measure of neuronal electrical activity in the brain. EEG 
is a promising diagnostic tool for disorders of the central nervous system, since it is low cost, non-invasive and 
currently implemented in healthcare systems around the world for diagnosis of  epilepsy7. The first interest in 
using EEG as a diagnostic tool for AD was motivated by the associations between AD and epileptic  activity8, 
but subsequent studies demonstrated limited success using epileptiform activity in the EEG to aid with the 
diagnosis of  AD9–11. For this reason, focus has since shifted to EEG signature activities not directly related to 
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network hyperexcitability, such as resting state power spectral and functional connectivity  analyses12. At present, 
EEG testing is not routine in assessment of AD as the sensitivity and specificity is not sufficiently high, but com-
monly used EEG signatures of AD including spectral slowing and altered functional  connectivity12 are typically 
assessed on a time scale of the order of seconds to  minutes13, assuming stationarity over these epochs. Using a 
combination of measures containing complementary information may achieve greater classification  accuracy14,15, 
therefore we hypothesise that combining these measures with analyses of non-stationarity within these epochs, 
novel information can be gained that can improve the ability of the EEG to classify  AD16,17.
One such method is EEG microstate analysis, which involves studying the instantaneous topographic maps of 
the  EEG18. Studies of EEG microstates have remarkably found the EEG to be comprised of only a small number of 
topographic  classes18, such that the EEG remains stable in a given class for periods of the order tens or hundreds 
of milliseconds before rapidly transitioning to another class. These rapidly switching periods of quasi-stability 
are hypothesised to be the electrophysiological correlates of the rapid activation and inactivation of the brain’s 
resting state networks relating to different functions underpinning information  processing19–24, earning micro-
states the nickname “atoms of thought”24. Thus, EEG microstates are a viable platform for exploring the changes 
in brain dynamics on the millisecond scale that may underpin impaired information processing and cognitive 
dysfunction in AD; indeed, alterations to microstates have been observed in healthy development and  aging25 
and a range of neurological disorders including frontotemporal dementia, schizophrenia, and  depression19. This 
makes EEG microstate analysis a suitable candidate for biomarkers at a faster temporal scale than power spectral 
or functional network analysis.
Much interest has been given to how properties such as duration, coverage, and topography of microstates 
are altered in neurological  disorders19. Alterations to patterns of transitions between classes have also been 
reported in neurological  disease26,27, suggesting that studying transitioning behaviour of microstates may give 
further mechanistic insights into cognitive impairment in AD as well as increasing sensitivity of electrophysi-
ological biomarkers. Indeed, recent studies have identified alterations to spatial patterns and temporal dynam-
ics of EEG microstates in AD and  MCI17,26,28,29. However, the ‘syntax analysis’26,27 used to analyse transitioning 
behaviour in these studies assumes the next microstate depends only on the present microstate (Markovian), 
and probabilities of transitions do not change over time (stationary). However, there is mounting evidence that 
microstate sequences are non-stationary and have non-Markovian transitioning  properties30–32. Here, we present 
a novel analysis of the transitioning behaviour of EEG microstates, which does not rely on these assumptions, 
by applying the Lempel–Ziv complexity (LZC)  algorithm33 to microstate sequences. LZC counts the number of 
unique sub-sequences within a sequence. Microstate sequences with low LZC are repetitive, exhibiting a limited 
number of transitioning patterns. Conversely high LZC is suggestive of complex transitioning. Because this 
measure does not make assumptions of Markovian transitioning, we hypothesise microstate LZC could aid with 
characterisation of the non-Markovian and non-stationary properties of temporal sequences of  microstates31,32. 
Microstate LZC could potentially give new insights into alterations to information processing and transitioning 
between active networks in AD on the millisecond scale, and act as a more sensitive EEG-based neurophysi-
ological signature of AD.
Here we explore microstate statistics in probable AD based on 20 s of resting state EEG, and the potential 
clinical applications of microstate LZC, combined with a power spectral  measure34, for classification of early 
stage non-medicated probable AD patients. We then test this classifier on an independent set of EEG recordings 
acquired with standard 19 electrode systems (used in clinical settings) in medicated AD patients from a distinct 
geographical location. Finally, since a key limitation of many past studies is the lack of longitudinal data, we make 
a preliminary exploration of the combination of microstates LZC and spectral power to predict the conversion 
of MCI to AD, based on a small MCI cohort followed up longitudinally for up to 4 years.
Methods
Participants. Detailed descriptions of participant recruitment, inclusion criteria, diagnosis of probable AD, 
and analysis of demographics are given in Supplementary Material 1. AD patients (n = 21, 8 male) and amnestic 
MCI patients (n = 25, 16 male) were recruited from memory clinics in the South West of England (SWE) follow-
ing clinical assessment on a consecutive incident patient basis. The diagnosis of probable AD was determined 
by clinical staff using neurological, neuroimaging, physical, and biochemical examination together with the 
results of family interview, neuropsychological, and daily living skills assessment according to DSM-IV35 and 
NINCDS-ADRDA  guidelines36. Age matched cognitively healthy older adult (HOA) controls (n = 26, 14 male) 
were recruited from the memory clinics’ volunteer panels; they had normal general health with no evidence of a 
dementing or other neuropsychological disorder, according to NINCDS-ADRDA  guidelines36. MCI participants 
who did not receive a dementia diagnosis within the four years following data acquisition were classified as 
stable (MCIs, n = 7, 5 male), those who had received an AD diagnosis were classified as converters (MCIc, n = 4, 
4 male), and the remaining patients were excluded from the analysis (see Supplementary Material 1). All partici-
pants were free from medication known to affect cognition. Cognitive status at the time of data acquisition was 
quantified using the mini-mental state examination (MMSE)37.
A test cohort of AD patients (n = 9, 3 male) and HOA controls (n = 7, 4 male) was used to test generalizability 
of EEG biomarkers. Patients were recruited on a consecutive incident basis from the Republic of San Marino 
(RSM) database of dementia. The diagnosis of probable AD was determined according to the IWG-2  criteria1 
by neurologists at the Republic of San Marino State Hospital. All AD patients underwent a neurological and 
functional examination, structural neuro-imaging (CT scan or MRI) and a full neuropsychological assessment. 
The inclusion criteria for the AD patients were a tau/Aβ42 ratio of > 0.52 at the CSF biochemical analysis and 
the presence of a significant episodic memory impairment as proved by a Memory Efficiency  Index38 < 1.2. The 
exclusion criteria were evidence of vascular lesions (including lacunar infarcts and deep white matter changes) 
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on structural neuroimaging and history or evidence of other neurological disorders or potential organic causes 
for memory disorders. Cognitively healthy controls were recruited from caregivers of patients and underwent 
a neurological examination and a neuropsychological assessment to exclude the presence of any cognitive dis-
order. In addition, all the AD patients from the San Marino cohort were being administered anticholinesterase 
drugs. Episodic memory impairment was quantified using the Rey Auditory Verbal Learning Test (RAVLT)39.
All participants provided written informed consent before participating and were free to withdraw at any 
time. All procedures were carried out in accordance with relevant guidelines and regulations; procedures were in 
accordance with the Declaration of Helsinki and approved by local ethics committees, i.e. the National Research 
Ethics Service Committee South West Bristol (Ref. 09/H0106/90) for the SWE cohorts and the Republic of San 
Marino Ethical Committee for Research and Experimentation (Ref. 0015 SM) and University of Exeter Medical 
School Research Ethics committee for the RSM cohort.
EEG collection and pre-processing. 20 s of resting-state, eyes-open EEG was used for all subjects. Data 
was sampled at 1000/512 Hz and recorded with 64/19 channels (SWE/RSM cohorts respectively). Data from 
both cohorts was pre-processed identically following previously described  steps34. Details of the 20  s epoch 
selection and pre-processing can be found in Supplementary Material 2.
Microstate analysis. Microstate extraction. Microstates were extracted using a k-means clustering meth-
od based on that of Koenig et al.40, using a k-means +  + algorithm used to select the initial k  maps41, and 20 
 repetitions40. The Krzanowski-Lai criterion was used to assess the optimum number of  microstates42. The me-
dian optimum over all subjects in the training set was k = 4, with no differences between groups. To ensure maps 
were comparable within cohorts (HOA or AD), a global clustering algorithm was  performed43 for each cohort, 
and global maps between cohorts were aligned by calculating correlation coefficients of the maps and visual 
inspection. Additional details can be found in Supplementary Material 2.
Basic microstate statistics. Mean microstate duration for each class and percent time spent within a class (cover-
age) were  calculated19. Analysis of microstate syntax, i.e. Markovian transitioning, was performed by extracting 
the transition matrix from the data by counting the number of transitions from class i to class j and normalizing 
by the total number of  transitions26,27. For all measures, a two-way ANOVA was performed to assess statistical 
differences. Since ANOVA tests are parametric, significant results were post-hoc validated using non-parametric 
Mann–Whitney U tests. For all Mann–Whitney U tests, we report the U-statistic and its z-score (under the nor-
mal approximation)44 along side the P value as a measure of effect size. Topographic differences between groups 
were assessed with class-wise topographic analyses of variance (TANOVA)23 (Supplementary Material 2). The 
minimum possible P-value was P = 0.001, deemed sufficient to identify significant differences in topographies.
Microstate complexity. Here we present a novel measure of EEG microstate transitioning that, unlike the Mark-
ovian syntax analysis, does not rely on assumptions of stationarity or  Markovianity32. The measure, referred to as 
C, involves calculating the Lempel–Ziv complexity (LZC)33 of the microstate transitioning sequence. The LZC of 
a string is defined as the number of different substrings within the string when read from left to right. A string 
is said to have low complexity if there are a small number of frequently repeating sequences. The algorithm for 
computing C is outlined in Supplementary Fig. S1 and Supplementary Material 3. LZC has in the past been used 
to calculate the complexity of a univariate EEG signal (Supplementary Material 3), but we believe use of this 
measure to explore the complexity of the microstate sequences is novel. All statistical comparisons of microstate 
LZC between groups was performed using non-parametric Mann–Whitney U tests.
Results
Participant demographics. Participant demographics, including age and neuropsychological scores, are 
outlined and analysed in Table 1, Supplementary Material 1and Supplementary Table S1–2. In both cohorts, 
AD patients demonstrated reduced neuropsychological test scores compared to cognitively healthy older adults 
(HOA). There were no differences in neuropsychological test score between MCI stable (MCIs) and MCI-to-AD 
converter (MCIc) at baseline.
Analysis of microstates in Alzheimer’s disease. Topographies for each of the four microstate classes 
in the SWE HOA and AD data are shown in Fig. 1, and in the HOA subjects largely align with the classical 
microstate classes A-D associated with wakeful  rest18,19, which are electrophysiological correlates of the audi-
tory (A), visual (B), saliency (C), and frontopariental working memory/attention (D) resting state  networks18,21. 
Class D was significantly altered in AD (P = 0.001; Fig. 1D). eLORETA was used to explore cortical generators 
underpinning this alteration (Supplementary Material 2). Figure 2A shows the eLORETA solution of the instan-
taneous map given by the difference of the global class D maps for HOA and AD. We subsequently calculated the 
eLORETA solution on a subject wise basis and calculated voxel-wise t-statistics to quantify spatially distributed 
differences in AD. Parietal sources were less activated in the AD subjects, particularly weighted more towards 
the left hemisphere (Fig. 2B,C).
Having found changes to the topography and underlying cortical generators to class D in AD, we next 
explored whether the transitioning behaviour of the microstate sequences were altered. For each subject and 
microstate class, mean duration, coverage, and the Markovian syntax transition matrix were extracted. Sup-
plementary Tables S3–S5 show the ANOVA tables for these tests. For mean duration, there was a significant 
disease group term (F = 9.95, P = 0.0019), suggesting a significant increase in mean microstate duration in AD, 
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averaged over all classes. We verified this significant increase in mean microstate duration with a non-parametric 
Mann–Whitney U test (U = 381, z = 2.30, P = 0.0214, Fig. 3A). No significant results were found for coverage of 
microstates or Markovian transitioning. All analyses were additionally conducted on a pairwise basis for class 
D to further verify that changes to the topography of this class in AD did not alter transitioning statistics. No 
significant differences were found.
Studies have suggested that microstate transitioning is non-Markovian30,32. We therefore additionally cal-
culated the Lempel–Ziv complexity (LZC) of the microstate transitioning sequence (C). C was significantly 
reduced in AD compared to HOA (U = 132.5, z = −3.05, P = 0.0023; Fig. 3B), suggesting that higher order or non-
Markovian alterations to microstate transitioning are present in the EEG of AD patients, to which a Markovian 
syntax analysis is not sensitive. Additionally, this effect size was notably larger than other classical measures of 
EEG complexity used in past AD literature (Fig. 3C,D, Supplementary Material 3).
Microstate complexity, combined with a single spectral feature, is a potentially useful bio-
marker of AD. Spectral slowing of the EEG in AD has been widely  reported12, and has been identified as a 
powerful tool for classification of AD from the  EEG14,15. A key aim of this study was to develop EEG microstate 
biomarkers for aiding diagnosis of AD, since we hypothesised that the difference in timescale between micro-
Table 1.  Data for healthy older adults and Alzheimer’s disease subjects for the training and test cohorts.
Cohort HOA AD MCI (stable) MCI (converter)
South West of England cohort
Age (± SEM; years) 76 (± 7) 79 (± 9) 80 (± 2) 76 (± 6)
MMSE (± SEM; 0–30) 29 (± 1) 23 (± 3) 25 (± 1) 26 (± 1)
N 26 21 7 4
Male 14 8 5 4
Female 12 13 2 0
San Marino cohort
Age (± SEM; years) 69 (± 2) 72 (± 2)
RAVLT Immediate Recall (± SEM; 0–75) 40 (± 6) 20 (± 5)




Figure 1.  Microstate topographies for the four classes. (Top) Globally clustered maps for HOA cohort, for 
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state measures and spectral measures would result in orthogonal information to increase classifier accuracy. 
Microstate LZC has a large effect size separating people with AD from controls and is uncorrelated with spectral 
slowing (Supplementary Material 3), so we next combined microstate LZC (C) with theta relative power (θRP), 
a proxy for slowing previously identified in this  dataset34 in a support vector machine (SVM) classifier (Sup-
plementary Material 2).
Table 2 shows the results of ten fold cross validation of the classifier, trained on the 64 channel SWE EEG 
analysed above. When features were combined, classification rate (CR), sensitivity, and specificity were all greater 
than 80%, with a CR of 85.1%, demonstrating a notable improvement over the use of these features independently. 
Figure 4A shows this classifier in 2D (θRP, C) space.
To test the classifier, the RSM cohort of clinical EEG was used as an independent test set. The SWE training 
data was spatially and temporally down-sampled to the same format as the RSM EEG, and the θRP + C classifier 
re-trained on this down-sampled data set. Table 2 and Fig. 4B show the results of the classifier on the independ-
ent RSM test data. The CR of the test data was 81.3% (13/16 subjects), with sensitivity 88.9% (8/9 AD patients 
classified as AD by the model) and specificity 71.4% (5/7 HOA subjects classified as HOA by the model). These 
results suggest the SVM classifier may be generalizable to new clinical data sets and is not due to overfitting to 
our data. However, to confirm this result a larger test dataset will be necessary.
Microstate complexity and slowing have predictive power for diagnosing prodromal 
AD. Finally, to test whether the classifier presented here may be useful as a tool for prodromal diagnosis of 
 AD1, i.e. predicting whether mild cognitive impairment (MCI) is due to prodromal AD, EEG recorded from a 
test set of MCI patients was classified by the model. Subjects were classified as MCIs or MCIc based on their 
clinical diagnosis four years following data acquisition. At the time of data acquisition, there was no difference in 
clinical diagnosis or MMSE scores for the subjects (Table 1, “Participant demographics” section).
Results of the classification are shown in Fig. 4C and Table 2. In this preliminary cohort, the model had a 
classification rate of 90.9%, correctly predicting the four-year diagnosis of 10/11 MCI patients. One MCIs subject 
was incorrectly classified as a converter.
Figure 2.  Cortical source generators underpinning alterations to microstate class D in AD. (A) Absolute value 
of the eLORETA solution to the instantaneous topography given by taking the difference between the global 
class D maps for HOA and AD. (B) t-statistic for voxel-wise comparisons of the subject-wise class D maps 
for HOA versus AD. Red indicates absolute value of current density is larger for HOA than AD, whilst blue 
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Discussion
The aim of this study was to explore microstate analysis as a predictive tool for the diagnosis of probable AD. A 
classifier was trained on a cohort of people with probable AD and cognitively healthy older adults recruited from 
the South West of England (SWE), using 64-channel EEG. Subsequently, the classifier was tested on an inde-
pendent cohort recruited from the Republic of San Marino (RSM), using a standard 19-channel EEG machine 
for clinical use. Whilst the RSM AD population was treated with acetylcholinesterase (AChE) inhibitors, the 
SWE cohort was unmedicated. This is an important fact in support of this method for early diagnosis, as the use 
of AChE inhibitors to treat people with AD is very common and a possible confounding factor for functional 
measures. The accuracy of our method was measured against a clinical diagnosis of probable AD based on IWG-
21 (test data) or DSM-IV35 and NINCDS-ADRDA  guidelines36 (training data).
Microstate complexity measure. In this work we present a novel application of Lempel–Ziv complexity 
(LZC)33 to microstate EEG sequences for the diagnosis of AD. LZC was chosen to study microstate transitions 
over classical Markovian syntax analysis since microstate transitioning is neither Markovian nor  stationary30,32. 
We found that the LZC of microstate transition sequences had a notably larger effect size in separating AD 
patients from controls than Markovian syntax analysis, suggesting higher order alterations to transitioning 
between microstates in AD.
Figure 3.  Microstate and complexity statistics are significantly altered in AD. (A) Mean duration of microstates. 
(B) Microstate LZC. (C) Ω-complexity. (D) Time series LZC. Descriptions of classical complexity measures 
C-D are given in Supplementary Material 3. Stars denote effect size of Mann–Whitney U test: *P < .05, **P < .01, 
***P < .001. Points next to boxplots show values for each participant.
Table 2.  Classification statistics from EEG measures in the training and test set.
Statistic (%)
SWE (HOA/AD) RSM (HOA/AD) MCIc/MCIs
C θRP C + θRP C + θRP C + θRP
Classification rate 68.1 72.3 85.1 81.3 90.9
Sensitivity 61.9 66.7 81.0 88.9 100
Specificity 73.1 76.9 88.5 71.4 85.7
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As a multivariate measure, microstate LZC additionally captures both spatial and temporal complexity, result-
ing in a larger effect size than previously reported measures of EEG complexity (Supplementary Material 3). 
A closely related univariate measure of EEG complexity is time series LZC, which has in the past been used to 
identify reduced complexity of the EEG in patients with AD by binarizing a univariate EEG time series based 
on a threshold and then calculating the LZC of this binary sequence (Supplementary Material 3). Application of 
LZC to the microstate sequences is an improvement over this method for several reasons. By using microstates, 
binning of the EEG is chosen based on repeating spatiotemporal patterns which have some neurophysiological 
basis related to active  networks18,23, as opposed to an arbitrary threshold. Furthermore, microstate LZC accounts 
for the multivariate nature of the EEG, not accounted for in classical time series LZC. Microstate LZC is a spatially 
extended version of the LZC method classically used in EEG literature. Finally, unlike time series  LZC45, micro-
state LZC is uncorrelated with EEG slowing (Supplementary Material 3), meaning it is a useful EEG biomarker 
of AD when combined with slowing.
Alterations to class D and the frontoparietal network. The topography of microstate class D was 
altered in AD. Previous studies give conflicting reports on alterations to microstate topographies in AD; in 
agreement with our results, Smailovic et  al.29 found alterations to the topography of class D in AD but also 
found alterations to class A, while Schumacher et al.28 found alterations to all classes in AD and Nishida et al.26 
found alterations to none. Differences in the number of channels is unlikely to explain these inconsistencies in 
results, as microstates are reliable with 8 or more  channels43. The use of eyes-open data is also an unlikely to give 
inconsistent  results46 (Supplementary Material 4). However, methodological differences may potentially explain 
opposing findings; in Nishida et al.26 all participants were used for defining the topographies of the four classes, 
in Smailovic et al.29 only the controls were used to define the classes, whilst in our study and that of Schumacher 
et al.28 classes were defined independently for each cohort. Additionally, Schumacher et al.28 used five microstate 
classes in their analysis, while the other studies discussed here used four.
It has been suggested that class D is related to the frontoparietal network and the attention and working 
memory cognitive  domains19,21,26,46. Reduced parietal activation underpinned the change in topography of class 
D in AD, supporting the hypothesis of dysfunction of the frontoparietal network. A possible mechanism for this 
is disrupted frontoparietal white matter integrity, since altered frontoparietal functional and effective connectivity 
have been reported in recent fMRI studies of  AD47,48.
Alterations to microstate duration and transitioning statistics. In this study, mean microstate 
duration was found to increase in AD. Reports of altered microstate duration are inconsistent in the past litera-
ture, which has found  increased28,29,49,  decreased16,50,51, or  unchanged17,26 durations in AD. Of these studies, four 
have used modern clustering methods comparable to this study. Two of these studies identified no differences 
in  duration17,26. Eyes-open versus eyes-closed EEG affects microstate duration (Supplementary Material 4)46, 
potentially explaining our conflicting results. Conversely, Smailovic et al.29 used modern clustering methods to 
study microstates from large cohorts of several hundred participants, and found increased mean duration in line 
with our results. Schumacher et al.28 also reported increased mean duration of microstates in AD in a smaller 
cohort. Interestingly, we might expect microstate duration to increase in AD due to slowing of the  EEG32 which 
is well established in  AD12—this was the original hypothesis made by Dierks et al.16, who expressed their surprise 
that a decreased microstate duration was found instead. Increased duration and reduced microstate LZC are 
Figure 4.  Separation of AD, HOA, and MCI using a SVM θRP + C classifier. The SVM predictor classifies points 
within the pale red region as AD and points within the gray region as HOA. (A) Training data set overlaid on 
64 channel model. (B) RSM data set overlaid on 19 channel classifier model. (C) MCI data set overlaid on 64 
channel model. All models were trained on the data set shown in A. Blue circles in A show the support vectors 
for training in the 64 channel model.
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suggestive of slower and more repetitive transitioning between active networks in AD, possibly indicating less 
complex information processing and giving insight into the mechanisms underpinning cognitive deficits in AD.
Limitations. There are some limitations to our study. A primary limitation is the sample size. Our training 
cohort from the south west of England consisted of 21 probable AD patients and 26 cognitively healthy controls. 
For a mechanistic study into microstate statistics, these numbers are consistent with other recent studies in the 
 field17,26,28. Many of the results presented here (increased microstate duration, altered topography of class D) 
were consistent with those of Smailovic et al.29, whose study consisted of several hundred participants, provid-
ing evidence to support that our results are unlikely to be of small sample size. However, it should be noted that 
Smailovic et al.29 also identified alterations to class A while our study did not, potentially as a result of lower 
power due to smaller sample size in our study. For clinical utility, the classifier should work on the individual 
level. Ultimately, larger cohorts will be required to quantify efficacy of the classifier. One strength of the study 
was the promising initial results from testing the classifier on an independent cohort and a cohort of people with 
MCI, a step which is not often done, but it should be noted that these sample sizes were even smaller (9 AD, 7 
controls, 11 MCI). Hence, the work presented here should be viewed as a preliminary study, and future work will 
involve further testing of these results in additional cohorts, particularly with respect to prediction of conversion 
from MCI.
A second limitation relates to the diagnostic criteria for participants. In the primary cohort of training data 
(and the MCI test data), diagnosis of AD was based on the DSM-IV35 and NINCDS-ADRDA  criteria36. Dubois 
et al.52 reviewed the limitations of these criteria, the foremost of which is limited specificity against other forms 
of dementia. In this study, these guidelines were used alongside neuroimaging and biochemical examination to 
provide in-vivo evidence of AD pathology, which is likely to improve  specificity52; nonetheless, at most here we 
can describe our participants as having “probable AD”, and results should be interpreted as such. The IWG-II 
 criteria1 are recent criteria for diagnosis of AD based on both clinical phenotype and in-vivo evidence of AD 
pathologies, which were used to diagnose AD in our test data. This inconsistency in diagnostic criteria between 
cohorts is a potential biasing factor for the study which should be explored further in future studies.
In addition to diagnostic criteria, several other factors differ between cohorts, for example medication and 
age. This is both a limitation and potential strength of the study; while differences between cohorts may reduce 
the power of the study, the results presented here suggest the classifier may be robust to these factors.
Conclusions
In this work we assessed microstate analysis, in combination with power spectral analysis, as a low-cost, non-
invasive tool for aiding the diagnosis of AD. Additionally, our observations can provide crucial insight into the 
mechanisms underpinning cognitive impairment in AD. Alterations to the frontoparietal network (namely 
parietal inactivation) was shown to relate to a changing topography in microstate class D. This network and 
microstate class are related to attention and working  memory21,26,46, which are impaired early in the AD  staging53. 
Microstate duration was found to increase in AD, whilst a novel application of Lempel–Ziv complexity to the 
microstate transitioning found decreased complexity in AD. These results are suggestive of slower and more 
repetitive microstate transitions, which potentially reflects similar attributes to the transitioning between active 
brain networks associated with a range of cognitive  domains19–24. Preliminary data suggest use of microstate 
complexity as a biomarker which can potentially aid with early diagnosis and prediction of future conversion 
to AD. Whilst medication is known to alter microstate  statistics54,55, our classifier retained high classification 
statistics for a probable AD diagnosis in an independent, medicated cohort.. The mechanistic insights presented 
in this study, paired to future, preclinical characterization of cellular correlates of microstate alterations in 
transgenic rodent models of AD pathologies may aid future drug development and more accurate diagnostic 
and prognostic tools for AD.
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